Towards curative cancer immunotherapy: Overcoming posttherapy tumor escape

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Zhou, Gang ^a   Levitsky, Hyam ^b,c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CANCER VACCINE; CETUXIMAB; GEMTUZUMAB; IBRITUMOMAB TIUXETAN; IPILIMUMAB; MONOCLONAL ANTIBODY; PANITUMUMAB; RITUXIMAB; SIPULEUCEL T; T LYMPHOCYTE RECEPTOR; TOSITUMOMAB; TRASTUZUMAB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MELANOMA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY;

COMBINED MODALITY THERAPY; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; NEOPLASMS; TUMOR ESCAPE;

EID: 84862272378     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/124187     Document Type: Review

References (141)

1. Dunn G. P., Old L. J., Schreiber R. D., The immunobiology of cancer immunosurveillance and immunoediting Immunity 2004 21 2 137 148 (Pubitemid 39094044)
2. Schreiber R. D., Old L. J., Smyth M. J., Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion Science 2011 331 6024 1565 1570
3. Mellman I., Coukos G., Dranoff G., Cancer immunotherapy comes of age Nature 2011 480 480 489
4. Hourigan C. S., Levitsky H. I., Evaluation of current cancer immunotherapy: hemato-oncology The Cancer Journal 2011 17 309 324
5. Beatty P. L., Cascio S., Lutz E., Tumor immunology: basic and clinical advances Cancer Research 2011 71 13 4338 4343
6. Soiffer R., Lynch T., Mihm M., Jung K., Rhuda C., Schmollinger J. C., Hodi F. S., Liebster L., Lam P., Mentzer S., Singer S., Tanabe K. K., Cosimi A. B., Duda R., Sober A., Bhan A., Daley J., Neuberg D., Parry G., Rokovich J., Richards L., Drayer J., Berns A., Clift S., Cohen L. K., Mulligan R. C., Drangf G., Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma Proceedings of the National Academy of Sciences of the United States of America 1998 95 22 13141 13146
7. Simons J. W., Jaffee E. M., Weber C. E., Levitsky H. I., Nelson W. G., Carducci M. A., Lazenby A. J., Cohen L. K., Finn C. C., Clift S. M., Hauda K. M., Beck L. A., Leiferman K. M., Owens A. H., Piantadosi S., Dranoff G., Mulligan R. C., Pardoll D. M., Marshall F. F., Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer Cancer Research 1997 57 8 1537 1546 (Pubitemid 27175572)
8. Simons J. W., Mikhak B., Chang J. F., DeMarzo A. M., Carducci M. A., Lim M., Weber C. E., Baccala A. A., Goemann M. A., Clift S. M., Ando D. G., Levitsky H. I., Cohen L. K., Sanda M. G., Mulligan R. C., Partin A. W., Carter H. B., Piantadosi S., Marshall F. F., Nelson W. G., Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer Cancer Research 1999 59 20 5160 5168 (Pubitemid 29503977)
9. Salgia R., Lynch T., Skarin A., Lucca J., Lynch C., Jung K., Hodi F. S., Jaklitsch M., Mentzer S., Swanson S., Lukanich J., Bueno R., Wain J., Mathisen D., Wright C., Fidias P., Donahue D., Clift S., Hardy S., Neuberg D., Mulligan R., Webb I., Sugarbaker D., Mihm M., Dranoff G., Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma Journal of Clinical Oncology 2003 21 4 624 630 (Pubitemid 46621895)
10. Jaffee E. M., Hruban R. H., Biedrzycki B., Laheru D., Schepers K., Sauter P. R., Goemann M., Coleman J., Grochow L., Donehower R. C., Lillemoe K. D., O'Reilly S., Abrams R. A., Pardoll D. M., Cameron J. L., Yeo C. J., Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation Journal of Clinical Oncology 2001 19 1 145 156 (Pubitemid 32063491)
11. Borrello I., Sotomayor E. M., Cooke S., Levitsky H. I., A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell- based vaccines Human Gene Therapy 1999 10 12 1983 1991 (Pubitemid 29387912)
12. Smith B. D., Kasamon Y. L., Kowalski J., Gocke C., Murphy K., Miller C. B., Garrett-Mayer E., Tsai H. L., Qin L., Chia C., Biedrzycki B., Harding T. C., Tu G. H., Jones R., Hege K., Levitsky H. I., K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate Clinical Cancer Research 2010 16 1 338 347
13. Kantoff P. W., Higano C. S., Shore N. D., Berger E. R., Small E. J., Penson D. F., Redfern C. H., Ferrari A. C., Dreicer R., Sims R. B., Xu Y., Frohlich M. W., Schellhammer P. F., Sipuleucel-T immunotherapy for castration-resistant prostate cancer The New England Journal of Medicine 2010 363 5 411 422
14. Rosenberg S. A., Yannelli J. R., Yang J. C., Topalian S. L., Schwartzentruber D. J., Weber J. S., Parkinson D. R., Seipp C. A., Einhorn J. H., White D. E., Treatment of patients with metastatic melanoma with autologous tumor- infiltrating lymphocytes and interleukin 2 Journal of the National Cancer Institute 1994 86 15 1159 1166 (Pubitemid 24249302)
15. Besser M. J., Shapira-Frommer R., Treves A. J., Zippel D., Itzhaki O., Hershkovitz L., Levy D., Kubi A., Hovav E., Chermoshniuk N., Shalmon B., Hardan I., Catane R., Markel G., Apter S., Ben-Nun A., Kuchuk I., Shimoni A., Nagler A., Schachter J., Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients Clinical Cancer Research 2010 16 9 2646 2655
16. Robbins P. F., Morgan R. A., Feldman S. A., Yang J. C., Sherry R. M., Dudley M. E., Wunderlich J. R., Nahvi A. V., Helman L. J., Mackall C. L., Kammula U. S., Hughes M. S., Restifo N. P., Raffeld M., Lee C. C. R., Levy C. L., Li Y. F., El-Gamil M., Schwarz S. L., Laurencot C., Rosenberg S. A., Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 Journal of Clinical Oncology 2011 29 7 917 924
17. Kochenderfer J. N., Wilson W. H., Janik J. E., Dudley M. E., Stetler-Stevenson M., Feldman S. A., Maric I., Raffeld M., Nathan D. A. N., Lanier B. J., Morgan R. A., Rosenberg S. A., Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Blood 2010 116 20 4099 4102
18. Porter D. L., Levine B. L., Kalos M., Bagg A., June C. H., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia The New England Journal of Medicine 2011 365 725 733
19. Brentjens R. J., Riviere I., Park J. H., Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias Blood 2011 118 4817 4828
20. Klebanoff C. A., Khong H. T., Antony P. A., Palmer D. C., Restifo N. P., Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy Trends in Immunology 2005 26 2 111 117
21. Nahta R., Esteva F. J., Herceptin: mechanisms of action and resistance Cancer Letters 2006 232 2 123 138 (Pubitemid 43170962)
22. Harbers S. O., Crocker A., Catalano G., D'Agati V., Jung S., Desai D. D., Clynes R., Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance The Journal of Clinical Investigation 2007 117 5 1361 1369 (Pubitemid 46718424)
23. Taylor C., Hershman D., Shah N., Suciu-Foca N., Petrylak D. P., Taub R., Vahdat L., Cheng B., Pegram M., Knutson K. L., Clynes R., Augmented HER-2-specific immunity during treatment with trastuzumab and chemotherapy Clinical Cancer Research 2007 13 17 5133 5143 (Pubitemid 47502081)
24. Peggs K. S., Segal N. H., Allison J. P., Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative Cancer Cell 2007 12 3 192 199 (Pubitemid 47333423)
25. Wolchok J. D., Yang A. S., Weber J. S., Immune regulatory antibodies: are they the next advance? The Cancer Journal 2010 16 4 311 317
26. Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., Van Den Eertwegh A. J. M., Lutzky J., Lorigan P., Vaubel J. M., Linette G. P., Hogg D., Ottensmeier C. H., Lebbé C., Peschel C., Quirt I., Clark J. I., Wolchok J. D., Weber J. S., Tian J., Yellin M. J., Nichol G. M., Hoos A., Urba W. J., Improved survival with ipilimumab in patients with metastatic melanoma The New England Journal of Medicine 2010 363 8 711 723
27. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., Lebbe C., Baurain J. F., Testori A., Grob J. J., Davidson N., Richards J., Maio M., Hauschild A., Miller W. H., Gascon P., Lotem M., Harmankaya K., Ibrahim R., Francis S., Chen T. T., Humphrey R., Hoos A., Wolchok J. D., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma The New England Journal of Medicine 2011 364 26 2517 2526
28. Keir M. E., Butte M. J., Freeman G. J., Sharpe A. H., PD-1 and its ligands in tolerance and immunity Annual Review of Immunology 2008 26 677 704 (Pubitemid 351600389)
29. Ahmadzadeh M., Johnson L. A., Heemskerk B., Wunderlich J. R., Dudley M. E., White D. E., Rosenberg S. A., Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired Blood 2009 114 8 1537 1544
30. Mumprecht S., Schrch C., Schwaller J., Solenthaler M., Ochsenbein A. F., Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression Blood 2009 114 8 1528 1536
31. Zhang L., Gajewski T. F., Kline J., PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model Blood 2009 114 8 1545 1552
32. Brahmer J. R., Drake C. G., Wollner I., Powderly J. D., Picus J., Sharfman W. H., Stankevich E., Pons A., Salay T. M., McMiller T. L., Gilson M. M., Wang C., Selby M., Taube J. M., Anders R., Chen L., Korman A. J., Pardoll D. M., Lowy I., Topalian S. L., Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates Journal of Clinical Oncology 2010 28 19 3167 3175
33. Sakuishi K., Apetoh L., Sullivan J. M., Blazar B. R., Kuchroo V. K., Anderson A. C., Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity Journal of Experimental Medicine 2010 207 10 2187 2194
34. Fourcade J., Sun Z., Benallaoua M., Guillaume P., Luescher I. F., Sander C., Kirkwood J. M., Kuchroo V., Zarour H. M., Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8 + T cell dysfunction in melanoma patients Journal of Experimental Medicine 2010 207 10 2175 2186
35. Woo S. R., Turnis M. E., Goldberg M. V., Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T cell function to promote tumoral immune escape Cancer Research 2012 72 4 917 927
36. Vonderheide R. H., Flaherty K. T., Khalil M., Stumacher M. S., Bajor D. L., Hutnick N. A., Sullivan P., Mahany J. J., Gallagher M., Kramer A., Green S. J., O'Dwyer P. J., Running K. L., Huhn R. D., Antonia S. J., Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody Journal of Clinical Oncology 2007 25 7 876 883 (Pubitemid 350002889)
37. Advani R., Forero-Torres A., Furman R. R., Rosenblatt J. D., Younes A., Ren H., Harrop K., Whiting N., Drachman J. G., Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma Journal of Clinical Oncology 2009 27 26 4371 4377
38. Beatty G. L., Chiorean E. G., Fishman M. P., Saboury B., Teitelbaum U. R., Sun W., Huhn R. D., Song W., Li D., Sharp L. L., Torigian D. A., O'Dwyer P. J., Vonderheide R. H., CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans Science 2011 331 6024 1612 1616
39. Zou W., Immunosuppressive networks in the tumour environment and their therapeutic relevance Nature Reviews Cancer 2005 5 4 263 274 (Pubitemid 40488632)
40. Vignali D. A. A., Collison L. W., Workman C. J., How regulatory T cells work Nature Reviews Immunology 2008 8 7 523 532
41. Gabrilovich D. I., Nagaraj S., Myeloid-derived suppressor cells as regulators of the immune system Nature Reviews Immunology 2009 9 3 162 174
42. Munn D. H., Mellor A. L., Indoleamine 2,3-dioxygenase and tumor-induced tolerance The Journal of Clinical Investigation 2007 117 5 1147 1154 (Pubitemid 46718399)
43. Opitz C. A., Litzenburger U. M., Sahm F., An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor Nature 2011 478 197 203
44. Moennikes O., Loeppen S., Buchmann A., Andersson P., Ittrich C., Poellinger L., Schwarz M., A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice Cancer Research 2004 64 14 4707 4710 (Pubitemid 38924510)
45. Quintana F. J., Basso A. S., Iglesias A. H., Korn T., Farez M. F., Bettelli E., Caccamo M., Oukka M., Weiner H. L., Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor Nature 2008 453 7191 65 71 (Pubitemid 351630328)
46. Sharma M. D., Baban B., Chandler P., Hou D. Y., Singh N., Yagita H., Azuma M., Blazar B. R., Mellor A. L., Munn D. H., Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase The Journal of Clinical Investigation 2007 117 9 2570 2582 (Pubitemid 47494358)
47. Ghiringhelli F., Menard C., Puig P. E., Ladoire S., Roux S., Martin F., Solary E., Le Cesne A., Zitvogel L., Chauffert B., Metronomic cyclophosphamide regimen selectively depletes CD4 + CD25 + regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunology, Immunotherapy 2007 56 5 641 648 (Pubitemid 46348738)
48. Moschella F., Valentini M., Aric E., Macchia I., Sestili P., D'Urso M. T., Alessandri C., Belardelli F., Proietti E., Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide Cancer Research 2011 71 10 3528 3539
49. Viaud S., Flament C., Zoubir M., Pautier P., LeCesne A., Ribrag V., Soria J. C., Marty V., Vielh P., Robert C., Chaput N., Zitvogel L., Cyclophosphamide induces differentiation of Th17 cells in cancer patients Cancer Research 2011 71 3 661 665
50. Proietti E., Moschella F., Capone I., Belardelli F., Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy Molecular Oncology 2012 6 1 1 14
51. Sistigu A., Viaud S., Chaput N., Bracci L., Proietti E., Zitvogel L., Immunomodulatory effects of cyclophosphamide and implementations for vaccine design Seminars in Immunopathology 2011 33 4 369 383
52. Machiels J. P. H., Todd Reilly R., Emens L. A., Ercolini A. M., Lei R. Y., Weintraub D., Okoye F. I., Jaffee E. M., Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage- colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice Cancer Research 2001 61 9 3689 3697 (Pubitemid 32694981)
53. Emens L. A., Asquith J. M., Leatherman J. M., Kobrin B. J., Petrik S., Laiko M., Levi J., Daphtary M. M., Biedrzycki B., Wolff A. C., Stearns V., Disis M. L., Ye X., Piantadosi S., Fetting J. H., Davidson N. E., Jaffee E. M., Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factorsecreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation Journal of Clinical Oncology 2009 27 35 5911 5918
54. Pellegrini M., Calzascia T., Elford A. R., Shahinian A., Lin A. E., Dissanayake D., Dhanji S., Nguyen L. T., Gronski M. A., Morre M., Assouline B., Lahl K., Sparwasser T., Ohashi P. S., Mak T. W., Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies Nature Medicine 2009 15 5 528 536
55. Prell R. A., Li B., Jian M. L., VanRoey M., Jooss K., Administration of IFN- enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine Cancer Research 2005 65 6 2449 2456 (Pubitemid 40490157)
56. Sikora A. G., Jaffarzad N., Hailemichael Y., Gelbard A., Stonier S. W., Schluns K. S., Frasca L., Lou Y., Liu C., Andersson H. A., Hwu P., Overwijk W. W., IFN- enhances peptide vaccine-induced CD8 + T cell numbers, effector function, and antitumor activity The Journal of Immunology 2009 182 12 7398 7407
57. Pace L., Vitale S., Dettori B., Palombi C., La Sorsa V., Belardelli F., Proietti E., Doria G., APC activation by IFN- decreases regulatory T cell and enhances Th cell functions The Journal of Immunology 2010 184 11 5969 5979
58. Lorenzi S., Mattei F., Sistigu A., Bracci L., Spadaro F., Sanchez M., Spada M., Belardelli F., Gabriele L., Schiavoni G., Type I IFNs control antigen retention and survival of CD8 + dendritic cells after uptake of tumor apoptotic cells leading to cross-priming The Journal of Immunology 2011 186 9 5142 5150
59. Rossi E. A., Goldenberg D. M., Cardillo T. M., Stein R., Chang C. H., CD20-targeted tetrameric interferon-, a novel and potent immunocytokine for the therapy of B-cell lymphomas Blood 2009 114 18 3864 3871
60. Xuan C., Steward K. K., Timmerman J. M., Morrison S. L., Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma Blood 2010 115 14 2864 2871
61. Weiss J. M., Back T. C., Scarzello A. J., Subleski J. J., Hall V. L., Stauffer J. K., Chen X., Micic D., Alderson K., Murphy W. J., Wiltrout R. H., Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment Proceedings of the National Academy of Sciences of the United States of America 2009 106 46 19455 19460
62. Curran M. A., Montalvo W., Yagita H., Allison J. P., PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proceedings of the National Academy of Sciences of the United States of America 2010 107 9 4275 4280
63. Mantovani A., Allavena P., Sica A., Balkwill F., Cancer-related inflammation Nature 2008 454 7203 436 444
64. Grivennikov S. I., Greten F. R., Karin M., Immunity, Inflammation, and Cancer Cell 2010 140 6 883 899
65. Demaria S., Pikarsky E., Karin M., Coussens L. M., Chen Y. C., El-Omar E. M., Trinchieri G., Dubinett S. M., Mao J. T., Szabo E., Krieg A., Weiner G. J., Fox B. A., Coukos G., Wang E., Abraham R. T., Carbone M., Lotze M. T., Cancer and inflammation: promise for biologic therapy Journal of Immunotherapy 2010 33 4 335 351
66. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M. C., Ullrich E., Saulnier P., Yang H., Amigorena S., Ryffel B., Barrat F. J., Saftig P., Levi F., Lidereau R., Nogues C., Mira J. P., Chompret A., Joulin V., Clavel-Chapelon F., Bourhis J., André F., Delaloge S., Tursz T., Kroemer G., Zitvogel L., Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Nature Medicine 2007 13 9 1050 1059 (Pubitemid 47517504)
67. Ghiringhelli F., Apetoh L., Tesniere A., Aymeric L., Ma Y., Ortiz C., Vermaelen K., Panaretakis T., Mignot G., Ullrich E., Perfettini J. L., Schlemmer F., Tasdemir E., Uhl M., Génin P., Civas A., Ryffel B., Kanellopoulos J., Tschopp J., André F., Lidereau R., McLaughlin N. M., Haynes N. M., Smyth M. J., Kroemer G., Zitvogel L., Activation of the NLRP3 inflammasome in dendritic cells induces IL-1 -dependent adaptive immunity against tumors Nature Medicine 2009 15 10 1170 1178
68. Obeid M., Tesniere A., Ghiringhelli F., Fimia G. M., Apetoh L., Perfettini J. L., Castedo M., Mignot G., Panaretakis T., Casares N., Métivier D., Larochette N., Van Endert P., Ciccosanti F., Piacentini M., Zitvogel L., Kroemer G., Calreticulin exposure dictates the immunogenicity of cancer cell death Nature Medicine 2007 13 1 54 61 (Pubitemid 46067386)
69. Mattarollo S. R., Loi S., Duret H., Ma Y., Zitvogel L., Smyth M. J., Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors Cancer Research 2011 71 14 4809 4820
70. Bos R., Sherman L. A., CD4 + T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8 + T lymphocytes Cancer Research 2010 70 21 8368 8377
71. Haabeth O. A. W., Lorvik K. B., Hammarstrm C., Donaldson I. M., Haraldsen G., Bogen B., Corthay A., Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer Nature Communications 2011 2 1, article A240
72. Rakhra K., Bachireddy P., Zabuawala T., Zeiser R., Xu L., Kopelman A., Fan A. C., Yang Q., Braunstein L., Crosby E., Ryeom S., Felsher D. W., CD4 + T Cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation Cancer Cell 2010 18 5 485 498
73. Ercolini A. M., Ladle B. H., Manning E. A., Pfannenstiel L. W., Armstrong T. D., Machiels J. P. H., Bieler J. G., Emens L. A., Reilly R. T., Jaffee E. M., Recruitment of latent pools of high-avidity CD8 + T cells to the antitumor immune response Journal of Experimental Medicine 2005 201 10 1591 1602 (Pubitemid 40723662)
74. Balachandran V.P., Cavnar M. J., Zeng S., Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido Nature Medicine 2011 17 1094 1100
75. Quezada S. A., Peggs K. S., Curran M. A., Allison J. P., CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells The Journal of Clinical Investigation 2006 116 7 1935 1945 (Pubitemid 44033317)
76. Kavanagh B., O'Brien S., Lee D., Hou Y., Weinberg V., Rini B., Allison J. P., Small E. J., Fong L., CTLA4 blockade expands FoxP 3 + regulatory and activated effector CD4 + T cells in a dose-dependent fashion Blood 2008 112 4 1175 1183
77. Valzasina B., Guiducci C., Dislich H., Killeen N., Weinberg A. D., Colombo M. P., Triggering of OX40 (CD134) on CD4 + CD25 + T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR Blood 2005 105 7 2845 2851 (Pubitemid 40446278)
78. Vu M. D., Xiao X., Gao W., Degauque N., Chen M., Kroemer A., Killeen N., Ishii N., Li X. C., OX40 costimulation turns off Foxp 3 + Tregs Blood 2007 110 7 2501 2510 (Pubitemid 47523172)
79. Piconese S., Valzasina B., Colombo M. P., OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection Journal of Experimental Medicine 2008 205 4 825 839 (Pubitemid 351549881)
80. Hirschhorn-Cymerman D., Rizzuto G. A., Merghoub T., Cohen A. D., Avogadri F., Lesokhin A. M., Weinberg A. D., Wolchok J. D., Houghton A. N., OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis Journal of Experimental Medicine 2009 206 5 1103 1116
81. Zhou G., Drake C. G., Levitsky H. I., Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines Blood 2006 107 2 628 636 (Pubitemid 43076387)
82. Zhou G., Levitsky H. I., Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance The Journal of Immunology 2007 178 4 2155 2162 (Pubitemid 46233413)
83. Nair R. E., Kilinc M. O., Jones S. A., Egilmez N. K., Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8 + T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors The Journal of Immunology 2006 176 12 7325 7334 (Pubitemid 43849033)
84. LaCelle M. G., Jensen S. M., Fox B. A., Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy Clinical Cancer Research 2009 15 22 6881 6890
85. Welters M. J. P., Kenter G. G., De Vos Van Steenwijk P. J., Lwik M. J. G., Berends-van Der Meer D. M. A., Essahsah F., Stynenbosch L. F. M., Vloon A. P. G., Ramwadhdoebe T. H., Piersma S. J., Van Der Hulst J. M., Valentijn A. R. P. M., Fathers L. M., Drijfhout J. W., Franken K. L. M. C., Oostendorp J., Fleuren G. J., Melief C. J. M., Van Der Burg S. H., Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses Proceedings of the National Academy of Sciences of the United States of America 2010 107 26 11895 11899
86. Rosenberg S. A., Yang J. C., Topalian S. L., Schwartzentruber D. J., Weber J. S., Parkinson D. R., Seipp C. A., Einhorn J. H., White D. E., Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 JAMA 1994 271 12 907 913
87. Cesana G. C., DeRaffele G., Cohen S., Moroziewicz D., Mitcham J., Stoutenburg J., Cheung K., Hesdorffer C., Kim-Schulze S., Kaufman H. L., Characterization of CD4 + CD25 + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma Journal of Clinical Oncology 2006 24 7 1169 1177 (Pubitemid 46638815)
88. Van Der Vliet H. J. J., Koon H. B., Yue S. C., Uzunparmak B., Seery V., Gavin M. A., Rudensky A. Y., Atkins M. B., Balk S. P., Exley M. A., Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer Clinical Cancer Research 2007 13 7 2100 2108 (Pubitemid 46649878)
89. Koreth J., Matsuoka K., Kim H. T., Interleukin-2 and regulatory T cells in graft-versus-host disease The New England Journal of Medicine 2011 365 2055 2066
90. Pasare C., Medzhitov R., Toll pathway-dependent blockade of CD4 + CD25 + T cell-mediated suppression by dendritic cells Science 2003 299 5609 1033 1036 (Pubitemid 36222922)
91. Yang Y., Huang C. T., Huang X., Pardoll D. M., Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance Nature Immunology 2004 5 5 508 515 (Pubitemid 38660463)
92. Peng G., Guo Z., Kiniwa Y., Voo K. S., Peng W., Fu T., Wang D. Y., Li Y., Wang H. Y., Wang R. F., Immunology: toll-like receptor 8-mediated reversal of CD4 + regulatory T cell function Science 2005 309 5739 1380 1384 (Pubitemid 41209366)
93. Caramalho I., Lopes-Carvalho T., Ostler D., Zelenay S., Haury M., Demengeot J., Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide Journal of Experimental Medicine 2003 197 4 403 411 (Pubitemid 36278597)
94. Crellin N. K., Garcia R. V., Hadisfar O., Allan S. E., Steiner T. S., Levings M. K., Human CD4 + T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP 3 in CD4 + CD25 + T regulatory cells The Journal of Immunology 2005 175 12 8051 8059 (Pubitemid 41798367)
95. Conroy H., Marshall N. A., Mills K. H. G., TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours Oncogene 2008 27 2 168 180
96. Rowswell-Turner R. B., Harden J. L., Nair R. E., Gu T., Kilinc M. O., Egilmez N. K., Chronic chemoimmunotherapy achieves cure of spontaneous murine mammary tumors via persistent blockade of posttherapy counter-regulation The Journal of Immunology 2011 187 4109 4118
97. Sharabi A., Laronne-Bar-On A., Meshorer A., Haran-Ghera N., Chemoimmunotherapy reduces the progression of multiple myeloma in a mouse model Cancer Prevention Research 2010 3 10 1265 1276
98. Piconese S., Pittoni P., Burocchi A., Gorzanelli A., Car A., Tripodo C., Colombo M. P., A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2 European Journal of Immunology 2010 40 10 2902 2913
99. Ruby C. E., Yates M. A., Hirschhorn-Cymerman D., Chlebeck P., Wolchok J. D., Houghton A. N., Offner H., Weinberg A. D., Cutting edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right The Journal of Immunology 2009 183 8 4853 4857
100. Mirmonsef P., Tan G., Zhou G., Morino T., Noonan K., Borrello I., Levitsky H. I., Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation Blood 2008 111 4 2112 2121 (Pubitemid 351451523)
101. Brody J. D., Goldstein M. J., Czerwinski D. K., Levy R., Immunotransplant preferentially expands Teffector cells over Tregulatory cells and cures large lymphoma tumors Blood 2009 113 1 85 94
102. Bayer A. L., Jones M., Chirinos J., Armas L. D., Schreiber T. H., Malek T. R., Levy R. B., Host CD4 + CD25 + T cells can expand and comprise a major component of the Treg compartment after experimental HCT Blood 2009 113 3 733 743
103. Powell D. J., De Vries C. R., Allen T., Ahmadzadeh M., Rosenberg S. A., Inability to mediate prolonged reduction of regulatory T cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy Journal of Immunotherapy 2007 30 4 438 447 (Pubitemid 46684433)
104. Horkheimer I., Quigley M., Zhu J., Huang X., Chao N. J., Yang Y., Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation Blood 2009 113 21 5330 5339
105. Dranoff G., GM-CSF-based cancer vaccines Immunological Reviews 2002 188 147 154 (Pubitemid 35398872)
106. Bronte V., Chappell D. B., Apolloni E., Cabrelle A., Wang M., Hwu P., Restifo N. P., Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8 + T cell responses by dysregulating antigen-presenting cell maturation The Journal of Immunology 1999 162 10 5728 5737 (Pubitemid 29314923)
107. Serafini P., Carbley R., Noonan K. A., Tan G., Bronte V., Borrello I., High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells Cancer Research 2004 64 17 6337 6343 (Pubitemid 39129439)
108. Lesokhin A., Hohl T. M., Kitano S., Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment Cancer Research 2012 72 4 876 886
109. Faries M. B., Hsueh E. C., Ye X., Hoban M., Morton D. L., Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine Clinical Cancer Research 2009 15 22 7029 7035
110. Filipazzi P., Valenti R., Huber V., Pilla L., Canese P., Iero M., Castelli C., Mariani L., Parmiani G., Rivoltini L., Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine Journal of Clinical Oncology 2007 25 18 2546 2553 (Pubitemid 47041228)
111. Slingluff C. L., Petroni G. R., Olson W. C., Smolkin M. E., Ross M. I., Haas N. B., Grosh W. W., Boisvert M. E., Kirkwood J. M., Chianese-Bullock K. A., Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8 + and CD4 + T-Cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial Clinical Cancer Research 2009 15 22 7036 7044
112. Bunt S. K., Yang L., Sinha P., Clements V. K., Leips J., Ostrand-Rosenberg S., Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression Cancer Research 2007 67 20 10019 10026 (Pubitemid 47621253)
113. He D., Li H., Yusuf N., Elmets C. A., Li J., Mountz J. D., Xu H., IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells The Journal of Immunology 2010 184 5 2281 2288
114. Rider P., Carmi Y., Guttman O., IL-1alpha and IL-1beta recruit different myeloid cells and promote different stages of sterile inflammation The Journal of Immunology 2011 187 4835 4843
115. Ben-Sasson S. Z., Hu-Li J., Quiel J., Cauchetaux S., Ratner M., Shapira I., Dinarello C. A., Paul W. E., IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation Proceedings of the National Academy of Sciences of the United States of America 2009 106 17 7119 7124
116. Li L., Kim J., Boussiotis V. A., IL-1 -mediated signals preferentially drive conversion of regulatory T cells but not conventional T cells into
117. Ben-Sasson S. Z., Caucheteux S., Crank M., Hu-Li J., Paul W. E., IL-1 acts on T cells to enhance the magnitude of in vivo immune responses Cytokines 2011 59 122 125
118. Song X., Voronov E., Dvorkin T., Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness The Journal of Immunology 2003 171 6448 6456 (Pubitemid 37532073)
119. Voronov E., Shouval D. S., Krelin Y., Cagnano E., Benharroch D., Iwakura Y., Dinarello C. A., Apte R. N., IL-1 is required for tumor invasiveness and angiogenesis Proceedings of the National Academy of Sciences of the United States of America 2003 100 5 2645 2650 (Pubitemid 36297552)
120. Apte R. N., Voronov E., Is interleukin-1 a good or bad guy in tumor immunobiology and immunotherapy? Immunological Reviews 2008 222 1 222 241 (Pubitemid 351430377)
121. Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G., Immunological aspects of cancer chemotherapy Nature Reviews Immunology 2008 8 1 59 73
122. Emens L. A., Chemoimmunotherapy The Cancer Journal 2010 16 4 295 303
123. Yamauchi K., Yang M., Hayashi K., Jiang P., Yamamoto N., Tsuchiya H., Tomita K., Moossa A. R., Bouvet M., Hoffman R. M., Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy Cancer Research 2008 68 2 516 520 (Pubitemid 351380079)
124. Daenen L. G., Roodhart J. M., van Amersfoort M., Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells Cancer Research 2011 71 6976 6985
125. Gingis-Velitski S., Loven D., Benayoun L., Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice Cancer Research 2011 71 6986 6996
126. Aggarwal B. B., Vijayalekshmi R. V., Sung B., Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe Clinical Cancer Research 2009 15 2 425 430
127. Gilbert L. A., Hemann M. T., DNA damage-mediated induction of a chemoresistant niche Cell 2010 143 3 355 366
128. Zou W., Chen L., Inhibitory B7-family molecules in the tumour microenvironment Nature Reviews Immunology 2008 8 6 467 477 (Pubitemid 351733418)
129. Terawaki S., Chikuma S., Shibayama S., Hayashi T., Yoshida T., Okazaki T., Honjo T., IFN- directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity The Journal of Immunology 2011 186 5 2772 2779
130. Kinter A. L., Godbout E. J., McNally J. P., The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands The Journal of Immunology 2008 181 6738 6746
131. Francisco L. M., Salinas V. H., Brown K. E., Vanguri V. K., Freeman G. J., Kuchroo V. K., Sharpe A. H., PD-L1 regulates the development, maintenance, and function of induced regulatory T cells Journal of Experimental Medicine 2009 206 13 3015 3029
132. Wang L., Pino-Lagos K., De Vries V. C., Guleria I., Sayegh M. H., Noelle R. J., Programmed death 1 ligand signaling regulates the generation of adaptive Foxp 3 + CD4 + regulatory T cells Proceedings of the National Academy of Sciences of the United States of America 2008 105 27 9331 9336
133. Currie A. J., Prosser A., McDonnell A., Cleaver A. L., Robinson B. W. S., Freeman G. J., Van Der Most R. G., Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation The Journal of Immunology 2009 183 12 7898 7908
134. Franceschini D., Paroli M., Francavilla V., Videtta M., Morrone S., Labbadia G., Cerino A., Mondelli M. U., Barnaba V., PD-L1 negatively regulates CD4 + CD25 + Foxp 3 + Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV The Journal of Clinical Investigation 2009 119 3 551 564
135. Johnson B. A., Baban B., L'Mellor A., Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy Immunotherapy 2009 1 4 645 661
136. Mellor A. L., Munn D. H., IDO expression by dendritic cells: tolerance and tryptophan catabolism Nature Reviews Immunology 2004 4 10 762 774 (Pubitemid 39336293)
137. Hou D. Y., Muller A. J., Sharma M. D., DuHadaway J., Banerjee T., Johnson M., Mellor A. L., Prendergast G. C., Munn D. H., Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses Cancer Research 2007 67 2 792 801 (Pubitemid 46192220)
138. Gu T., Rowswell-Turner R. B., Kilinc M. O., Egilmez N. K., Central role of IFN -indoleamine 2,3-dioxygenase axis in regulation of interleukin-12- mediated antitumor immunity Cancer Research 2010 70 1 129 138
139. Webster W. S., Thompson R. H., Harris K. J., Frigola X., Kuntz S., Inman B. A., Dong H., Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine The Journal of Immunology 2007 179 5 2860 2869
140. Mkrtichyan M., Najjar Y. G., Raulfs E. C., Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms European Journal of Immunology 2011 41 2977 2986
141. Kohlmeyer J., Cron M., Landsberg J., Bald T., Renn M., Mikus S., Bondong S., Wikasari D., Gaffal E., Hartmann G., Tting T., Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy Cancer Research 2009 69 15 6265 6274